天健审〔2025〕4473 号 中牧实业股份有限公司全体股东： 我们接受委托，审计了中牧实业股份有限公司（以下简称中牧股份）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度 的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变 动表，以及财务报表附注，并出具了审计报告。在此基础上，我们审计了后附的 中牧股份管理层编制的 2024 年度《非经营性资金占用及其他关联资金往来情况 汇总表》（以下简称汇总表）。 一、对报告使用者和使用目的的限定 目 录 一、非经营性资金占用及其他关联资金往来情况的专项 | | | 二、非经营性资金占用及其他关联资金往来情况汇总表……………第 3 页 三、执业资格证书…………………………………………………… 第 4—8 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 本报告仅供中牧股份年度报告披露时使用，不得用作任何其他目的。我们同 意将本报告作为中牧股份年度报告的必备文件，随同其他文件一起报送并对外披 露。 为了更好地理解中牧股份 2024 年度非经营性资金占用及其他关联资金往来 情况，汇总表应当与已 ...

年度中牧实业股份有限公司 环境、社会和公司治理 (ESG)报告 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 股票简称：中牧股份 股票代码：600195 上海证券交易所上市发行 保护动物安全 关爱人类健康 Animal Protection and Human Healthcare 中牧实业股份有限公司 关于本报告 本报告是中牧实业股份有限公司发布的第十七份环境、社会和公司治理（ESG）/社会责任报告，本着客观、规范、透明和全 面的原则，详细披露了中牧股份 2024年在积极承担社会责任、有效管理 ESG风险与机遇等方面的具体举措、重点实践、亮 点案例和关键绩效，旨在回应利益相关方的期望，未来更好地履行社会责任。 时间范围 本报告涵盖期间为 2024年 1月 1日至 12月 31日。为增强本 报告的对比性和前瞻性，部分内容适当追溯以往年份或具 有前瞻性描述。 报告范围 电话：010-63701111 传真：010-63701950 网址：www.cahic.com 地址：北京市丰台区南四环西路188号总部基地八区16-17号楼 本报告以中牧实业股份有限公司为主体，包括下 ...

中牧实业股份有限公司董事会 公司独立董事符合《上市公司独立董事管理办法》《上海证券交 易所上市公司自律监管指引第 1 号—规范运作》等法律法规中关于独 立董事任职资格及独立性的要求，不存在任何妨碍其进行独立客观判 断的关系，不存在影响独立董事独立性的情况。 中牧实业股份有限公司董事会 2025 年 4 月 10 日 关于对独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所上市公司 自律监管指引第 1 号—规范运作》等要求，并结合独立董事出具的《中 牧实业股份有限公司独立董事关于独立性情况的自查报告》，中牧实 业股份有限公司(以下简称"公司")董事会就公司在任独立董事唐功 远、谯仕彦、胡燕的独立性情况进行评估并出具如下专项意见： ...

召开地点：北京市丰台区南四环西路 188 号总部基地 8 区 16 号楼 8 层公司 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 13 日 股票代码：600195 股票简称：中牧股份 公告编号：2025-008 中牧实业股份有限公司 关于召开2024年年度股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2025 年 5 月 13 日 13 点 30 分 本次股东会还将听取独立董事 2024 年度述职报告。 至2025 年 5 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 股东会召开日期：2025年5月13日 本次股东会采用的网络投票系统：上海证券交易所股 ...

股票代码：600195 股票简称：中牧股份 编号：临 2025-006 中牧实业股份有限公司 第九届监事会第一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中牧实业股份有限公司（以下简称"公司"或"中牧股份"）第九届监事会第一 次会议通知于 2025 年 3 月 28 日通过公司电子办公系统、电子邮件等形式发出，会 议于 2025 年 4 月 10 日在北京市丰台区总部基地八区 16 号楼 801 会议室以现场结合 视频的方式召开，会议应到监事 3 名，实到监事 3 名。会议由监事会主席侯士忠先 生主持，符合《公司法》《公司章程》的规定。 经与会监事认真审议，会议表决通过如下议案： 一、中牧股份 2024 年度监事会工作报告 表决结果：3 票同意，0 票反对，0 票弃权。 报告期内，监事会认真审阅了 2024 年度内的定期报告并出具了书面审核意见。 经审阅，监事会认为公司 2024 年度内的定期报告的编制和审议程序均符合法律、法 规、《公司章程》和公司内部管理制度的各项规定；内容和格式均符合中国证监会和 上海 ...

股票代码：600195 股票简称：中牧股份 编号：临 2025-005 中牧实业股份有限公司 第九届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中牧实业股份有限公司（以下简称"公司"或"中牧股份"）第九届董事会第 一次会议通知于 2025 年 3 月 28 日通过公司电子办公系统、电子邮件等形式发出， 会议于 2025 年 4 月 10 日在北京市丰台区总部基地八区 16 号楼 801 会议室以现场 结合视频的方式召开，会议应到董事 6 名，实到董事 6 名。公司监事、高管人员列 席本次会议。会议由董事长吴冬荀先生主持，符合《公司法》《公司章程》的规定。 经与会董事审议，会议表决通过如下议案： 一、中牧股份 2024 年度董事会工作报告 本报告在提交董事会前已经公司董事会审计委员会审议通过。 表决结果：6 票同意，0 票反对，0 票弃权。 该报告需提交公司 2024 年年度股东会审议。 二、中牧股份 2024 年度总经理工作报告 表决结果：6 票同意，0 票反对，0 票弃权。 三、中牧股份董事会审 ...

股票代码：600195 股票简称：中牧股份 编号：临 2025-007 如在本公告披露之日起至实施权益分派的股权登记日期间，因可转债转股、回 购股份、股权激励授予股份回购注销、重大资产重组股份回购注销等致使公司总股 本发生变动的，公司拟维持现金分红总额不变，相应调整每股分配比例。如后续总 股本发生变动，公司将另行公告具体调整情况。 中牧实业股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、利润分配预案内容 （一）利润分配预案的具体内容 经天健会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公司 母公司报表中期末未分配利润为 2,771,271,035.53 元。经董事会决议，公司 2024 年 年度拟以实施权益分派股权登记日登记的总股本为基数分配利润。本次利润分配预 案如下： 公司拟向全体股东每股派发现金红利 0.023 元（含税）。截至 2024 年 12 月 31 日，公司总股本 1,021,148,260 股，以此计算合计拟派发现金 ...

Financial Performance - The company's operating revenue for 2024 reached CNY 6,017,190,375.67, an increase of 11.30% compared to CNY 5,406,312,590.46 in 2023[21] - The net profit attributable to shareholders of the listed company was CNY 70,884,445.64, a decrease of 82.41% from CNY 403,051,611.99 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 62,137,902.01, down 77.72% from CNY 278,858,364.79 in 2023[21] - The net cash flow from operating activities was CNY 419,565,593.23, an increase of 12.65% compared to CNY 372,461,428.84 in 2023[21] - Basic earnings per share decreased by 82.42% to CNY 0.0694 compared to CNY 0.3947 in 2023[22] - Net profit attributable to shareholders decreased by 82.41% due to a decline in gross profit and investment income[22] - The weighted average return on equity decreased by 6.17 percentage points to 1.29% from 7.46% in 2023[22] Assets and Liabilities - The total assets at the end of 2024 were CNY 8,843,999,066.31, a decrease of 1.14% from CNY 8,946,377,928.42 at the end of 2023[21] - The net assets attributable to shareholders of the listed company were CNY 5,505,042,539.52, a slight decrease of 0.28% from CNY 5,520,675,866.70 at the end of 2023[21] - The company reported a net cash outflow from financing activities of ¥496,179,946.71, a significant decrease of 165.34% compared to the previous year, primarily due to increased cash used for debt repayment[46] - The accounts payable increased by 291.84% to ¥255,443,942.00, indicating a rise in external payment obligations[59] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.23 per 10 shares, totaling CNY 23,486,409.98, based on a total share capital of 1,021,148,260 shares[6] - The cash dividend distribution for the year 2023 is set at 0.119 yuan per share, totaling approximately 121.52 million yuan, which represents about 30.15% of the net profit attributable to shareholders[146] - The cumulative cash dividend amount over the last three accounting years is approximately 328.81 million yuan, with a cash dividend ratio of 96.33% based on the average annual net profit[151] Research and Development - The company is committed to high-quality development and innovation as part of its strategic goals for the "14th Five-Year Plan" period[32] - R&D expenses increased by 17.13% to ¥143,898,523.68, primarily due to higher direct material and testing costs associated with R&D projects[46] - Total R&D investment amounted to ¥159,306,758.78, representing 2.65% of operating revenue[54] - The number of R&D personnel is 468, accounting for 11% of the total workforce[55] - The company is actively involved in the research and development of various vaccines, including a rabies inactivated vaccine and a vaccine for pseudorabies in pigs[71] Market and Product Development - The company achieved a significant market share in key products such as foot-and-mouth disease vaccine and ST pig fever vaccine, with a focus on large clients and major products[32] - The company is actively expanding its product offerings in the pet market, integrating various marketing strategies and accelerating product development[34] - The company is expanding its product offerings in pet nutrition and health products[73] - The company plans to expand its international market presence as part of its "Belt and Road" initiative, enhancing competitiveness[100] Corporate Governance and Compliance - The company emphasizes that forward-looking statements in the report do not constitute substantive commitments to investors, highlighting potential investment risks[7] - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5] - The company is committed to enhancing corporate governance and compliance with legal regulations, ensuring no insider trading incidents occurred during the reporting period[112] - The company’s audit committee emphasized the importance of independent and objective auditing practices, contributing to improved corporate governance and internal control[131] Environmental and Social Responsibility - The company invested approximately ¥29.83 million in environmental protection during the reporting period[157] - The company has implemented comprehensive pollution prevention measures, ensuring that all wastewater and waste gas meet discharge standards[160] - Total investment in poverty alleviation and rural revitalization projects amounted to 1.32 million CNY, with 1.1 million CNY allocated for targeted assistance in Xiaoxian County[175] - The company donated a total of 150,000 CNY to charity initiatives, including 100,000 CNY for the "Charity One Day Donation" event in Linyi City[174] Strategic Planning and Future Outlook - The company aims to enhance its position as a leader in the animal health and feed additive industry, focusing on green development and innovation[99] - The company plans to balance traditional industry upgrades with the development of strategic emerging industries to enhance competitiveness and resilience in the supply chain[105] - The company will strengthen risk prevention measures to ensure safety in development and maintain national security responsibilities[107] - The company provided a positive outlook for the next quarter, projecting a revenue increase of 25% to 1.875 billion RMB[119]

中牧股份（600195）公告，2024年营业收入60.17亿元，同比增长11.30%。归属于上市公司股东的净利 润7088.44万元，同比下降82.41%。向全体股东每10股派发现金红利0.23元，共计派发现金红利2348.64 万元。 ...

Core Insights - The global animal vaccine market is projected to exceed $14 billion in 2024, following a market size of over $13.5 billion in 2023, with a compound annual growth rate (CAGR) of 10.10% over the past five years [1][8]. Market Overview - Animal vaccines, also known as veterinary vaccines, are products made from pathogenic microorganisms that stimulate the immune system of animals to produce specific antibodies, thereby preventing infectious diseases [1]. - North America, including the United States and Canada, is the largest regional market for animal vaccines, accounting for approximately 45% of the global market share in 2023 [3]. Industry Competition - Leading companies in the global animal vaccine industry offer a diverse range of products, including vaccines for pets, pigs, poultry, ruminants, and aquaculture [5]. - Major players such as Merck Animal Health, Zoetis, and Boehringer Ingelheim have established multiple production bases worldwide, indicating significant production capacity [5]. Company Profiles - **Merck Animal Health**: Offers pet vaccines, pig vaccines, poultry vaccines, and aquaculture vaccines, with 29 production bases across 12 countries, including a major facility in Suzhou, China [6]. - **Zoetis**: Operates production bases in the United States and China, having established its first R&D and production base in China in 2019 [6]. - **Boehringer Ingelheim**: Maintains over 20 production bases globally, with two facilities located in Nanchang and Taizhou, China [6]. - **Hualan Biological Engineering**: Initially focused on blood products, it has become a major producer of influenza vaccines in China, accounting for over 40% of the national market [6]. - **Fubao Animal Health**: Produces vaccines for pigs, poultry, and aquaculture, with production bases in the United States and Suzhou, China [6].